The measurement of symptoms in young children with cancer: The validation of the Memorial Symptom Assessment Scale in children aged 7-12
The measurement of symptoms in young children with cancer: The validation of the Memorial Symptom Assessment Scale in children aged 7-12
复制标题
DOI：
10.1016/s0885-3924(01)00375-x
复制
发表时间：
2002-01-01
影响因子：
4.7
通讯作者：
Portenoy, RK
中科院分区：
文献类型：
--
作者：
Collins, JJ;Devine, TD;Portenoy, RK
很少有研究试图描述患有癌症的幼儿的症状经历。部分原因是缺乏针对该患者人群的有效症状评估量表。本研究的目的是评估修订的记忆症状评估量表（MSAS）的信度和效度在7-12岁的患者作为一种工具，用于评估儿童癌症的症状。MSAS（7-12岁）适用于149名儿童（住院和门诊患者），这些儿童在英国伦敦的皇家马斯登NHS信托或澳大利亚悉尼Westmead的儿童医院接受治疗。有效性进行了评估，通过比较与医疗记录，父母的报告，并同时评估视觉模拟量表的选定症状。这些数据提供了MSAS（7-12）的可靠性和有效性的证据，并证明7岁的癌症儿童可以报告有关其症状经历的临床相关和一致的信息。患有癌症的幼儿会出现多种症状。大约三分之一的人在完成MSAS之前的48小时内经历了嗜睡和/或疼痛和/或失眠（7-12）。MSAS（7-12岁）的完成率很高，大多数儿童在很短的时间内完成了该工具，并且没有什么困难。该工具似乎是年龄适当的，可能有助于年龄较大的儿童无法独立完成MSAS（10-18）。系统的症状评估可能有助于未来症状的流行病学研究和癌症化疗药物试验。疼痛症状管理杂志2002：23：10-16（C）癌症疼痛缓解委员会，2002年。
Few studies have attempted to describe the experience of symptoms in young children with cancer. This is due, in part, to the lack of validated symptom assessment scales for this patient population. The objective of this study was to evaluate the reliability and validity of a revised Memorial Symptom Assessment Scale (MSAS) in patients aged 7-12 as an instrument for the assessment of symptoms in young children with cancer. The MSAS (7-12) was administered to 149 children (inpatients and outpatients) who were undergoing treatment at either the Royal Marsden NHS Trust, London, United Kingdom or The Children's Hospital at Westmead, Sydney Australia. Validity was evaluated by comparison with the medical record, parental report, and concurrent assessment on visual analogue scales for selected symptoms. The data provide evidence of the reliability and validity of MSAS (7-12) and demonstrate that children with cancer as young as 7 years can report clinically relevant and consistent information about their symptom experience. Young children with cancer experience multiple symptoms. Approximately one-third had experienced lethargy and/or pain and/or insomnia during the 48 hours prior to the completion of MSAS (7-12). The completion rate of MSAS (7-12) was high and the majority of children completed the instrument in a short period of time and with little difficulty. The instrument appears to be age appropriate and may be helpful to older children unable to independently complete MSAS (10-18). Systematic symptom assessment may be useful in future epidemiological studies of symptoms and in cancer chemotherapy drug trial. J Pain Symptom Manage 2002:23:10-16 (C) Cancer Pain Relief Committee, 2002.